Abstract 2606: A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer

A. G. Capitán, J. Bracht, N. Potie, M. González-Cao, S. Viteri, A. Martínez-Bueno, C. Cabrera-Gálvez, P. Rubinstein, C. Mayo-de-las-Casas, J. Valarezo, chung-Ying Huang, C. Pedraz, Richard Boykind, S. Warren, R. Rosell, Miguel Ángel Molina-Vilaa, A. Aguilar-Hernández
{"title":"Abstract 2606: A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer","authors":"A. G. Capitán, J. Bracht, N. Potie, M. González-Cao, S. Viteri, A. Martínez-Bueno, C. Cabrera-Gálvez, P. Rubinstein, C. Mayo-de-las-Casas, J. Valarezo, chung-Ying Huang, C. Pedraz, Richard Boykind, S. Warren, R. Rosell, Miguel Ángel Molina-Vilaa, A. Aguilar-Hernández","doi":"10.1158/1538-7445.AM2021-2606","DOIUrl":null,"url":null,"abstract":"Background: 80% of non-small cell lung cancer (NSCLC) cases are diagnosed at stages IIIB-IV and have a dismal prognosis with a median life expectancy that does not exceed 2 years. In contrast, patients diagnosed at early and locally advanced stages (I-IIIA) can undergo surgery and have the potential to be totally cured. Imaging technologies often detect lung nodules of unknown significance that pose a diagnostic challenge; some patients with benign nodules are submitted to unnecessary surgical interventions while others with small tumors are just kept in observation, risking a significant delay for treatment. A diagnostic test that could differentiate between benign and malignant masses would be of great help in this setting. Methods: Circulating-free RNA (cfRNA) was isolated from the plasma of healthy individuals (N=21), early(I-II) stage (N=22) and stage IIIA (N=12) NSCLC patients, using an automatic extraction method(Qiasymphony, Qiagen). Purified cfRNA was quantified using Qubit, retrotranscribed and pre-amplified (14cycles) using the Low RNA Input Amplification kit (NanoString Technologies). Gene expression analysis was performed on the nCounter platform using the PanCancer IO360TM (NanoString Technologies), which can detect 770 transcripts related to tumor biology, micro-environment and the immune system. Results: Gene expression analysis revealed differential patterns for some cf-mRNAs from localized stage NSCLC patients versus healthy controls. A bioinformatics recursive feature elimination algorithm selected a 16-gene mRNA signature that was able to distinguish between localized NSCLC and control samples with an area under the ROC curve of 0.91 to 0.95. Furthermore, the signature scores derived from the algorithm were significantly different between the two cohorts. Conclusions: We have found an 16-gene signature that can differentiate between cfRNA of localized stages NSCLC patients and control individuals. Our results warrant validation studies in larger cohorts. Citation Format: Ana Gimenez Capitan, Jillian Bracht, Nicolas Potie, Maria Gonzalez-Cao, Santiago Viteri, Alejandro Martinez-Bueno, Carlos Cabrera-Galvez, Pablo Rubinstein, Clara Mayo-de-las-Casas, Joselyn Valarezo, Chung-Ying Huang, Carlos Pedraz, Richard Boykind, Sarah Warren, Rafael Rosell, Miguel Angel Molina-Vilaa, Andres Aguilar-Hernandez. A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2606.","PeriodicalId":20290,"journal":{"name":"Prevention Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prevention Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-2606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: 80% of non-small cell lung cancer (NSCLC) cases are diagnosed at stages IIIB-IV and have a dismal prognosis with a median life expectancy that does not exceed 2 years. In contrast, patients diagnosed at early and locally advanced stages (I-IIIA) can undergo surgery and have the potential to be totally cured. Imaging technologies often detect lung nodules of unknown significance that pose a diagnostic challenge; some patients with benign nodules are submitted to unnecessary surgical interventions while others with small tumors are just kept in observation, risking a significant delay for treatment. A diagnostic test that could differentiate between benign and malignant masses would be of great help in this setting. Methods: Circulating-free RNA (cfRNA) was isolated from the plasma of healthy individuals (N=21), early(I-II) stage (N=22) and stage IIIA (N=12) NSCLC patients, using an automatic extraction method(Qiasymphony, Qiagen). Purified cfRNA was quantified using Qubit, retrotranscribed and pre-amplified (14cycles) using the Low RNA Input Amplification kit (NanoString Technologies). Gene expression analysis was performed on the nCounter platform using the PanCancer IO360TM (NanoString Technologies), which can detect 770 transcripts related to tumor biology, micro-environment and the immune system. Results: Gene expression analysis revealed differential patterns for some cf-mRNAs from localized stage NSCLC patients versus healthy controls. A bioinformatics recursive feature elimination algorithm selected a 16-gene mRNA signature that was able to distinguish between localized NSCLC and control samples with an area under the ROC curve of 0.91 to 0.95. Furthermore, the signature scores derived from the algorithm were significantly different between the two cohorts. Conclusions: We have found an 16-gene signature that can differentiate between cfRNA of localized stages NSCLC patients and control individuals. Our results warrant validation studies in larger cohorts. Citation Format: Ana Gimenez Capitan, Jillian Bracht, Nicolas Potie, Maria Gonzalez-Cao, Santiago Viteri, Alejandro Martinez-Bueno, Carlos Cabrera-Galvez, Pablo Rubinstein, Clara Mayo-de-las-Casas, Joselyn Valarezo, Chung-Ying Huang, Carlos Pedraz, Richard Boykind, Sarah Warren, Rafael Rosell, Miguel Angel Molina-Vilaa, Andres Aguilar-Hernandez. A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2606.
摘要:血浆中基于ncounter的mRNA信号与局限性非小细胞肺癌有关
背景:80%的非小细胞肺癌(NSCLC)病例诊断为iib - iv期,预后不佳,中位预期寿命不超过2年。相比之下,在早期和局部晚期(I-IIIA)诊断的患者可以接受手术,并有可能完全治愈。影像学技术经常检测到意义不明的肺结节,对诊断构成挑战;一些患有良性结节的患者接受了不必要的手术干预,而另一些患有小肿瘤的患者只是保持观察,这可能会严重延误治疗。在这种情况下,能够区分良性和恶性肿块的诊断测试将大有帮助。方法:采用Qiasymphony、Qiagen自动提取方法,从健康个体(N=21)、早期(I-II)期(N=22)和IIIA期(N=12) NSCLC患者血浆中分离游离循环RNA (cfRNA)。纯化的cfRNA使用量子比特进行定量,使用低RNA输入扩增试剂盒(NanoString Technologies)进行反转录和预扩增(14个周期)。在nCounter平台上使用PanCancer io360™(NanoString Technologies)进行基因表达分析,该平台可检测770个与肿瘤生物学、微环境和免疫系统相关的转录本。结果:基因表达分析揭示了局部分期NSCLC患者与健康对照者的一些cf- mrna的差异模式。生物信息学递归特征消除算法选择了一个16个基因的mRNA特征,该特征能够区分局部NSCLC和对照样本,ROC曲线下面积为0.91至0.95。此外,该算法得出的签名分数在两个队列之间存在显著差异。结论:我们发现了一个16个基因的特征,可以区分局部分期NSCLC患者和对照个体的cfRNA。我们的结果保证在更大的队列中进行验证研究。引文格式:Ana Gimenez Capitan、Jillian Bracht、Nicolas Potie、Maria Gonzalez-Cao、Santiago Viteri、Alejandro Martinez-Bueno、Carlos Cabrera-Galvez、Pablo Rubinstein、Clara Mayo-de-las-Casas、joseyn Valarezo、Chung-Ying Huang、Carlos Pedraz、Richard Boykind、Sarah Warren、Rafael Rosell、Miguel Angel Molina-Vilaa、Andres Aguilar-Hernandez。血浆中基于ncounter的mRNA信号与局限性非小细胞肺癌有关[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):2606。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信